“Our collaboration with Acadia leverages their robust expertise in neuroscience development and commercialization, positioning SAN711 as a promising option for neurological disorders while enabling us to advance several of our other valuable pipeline programs to key inflection points,” said Thomas Feldthus, CEO of Saniona. “Acadia’s commitment aligns with our mission to improve outcomes for those affected by neurological disorders, and together, we aim to expand treatment possibilities for patients in need.”

As a first indication, Acadia plans to pursue development of SAN711 for essential tremor, a neurological condition that includes shaking or trembling movements in one or more parts of the body. Acadia is planning to initiate a Phase 2 study of SAN711 in essential tremor in 2026. Acadia will lead and finance further clinical development, regulatory submissions, and global commercialization efforts for SAN711. Saniona will continue overseeing the ongoing Phase 1 study and provide support for Phase 2 preparation.

Under the terms of the License Agreement, Saniona will receive US $28 million in upfront plus potential milestone payments of up to US $582 million, of which the first milestone payment of US $10 million will be payable upon initiation of the first Phase 2 study. In addition, Saniona is eligible to receive tiered royalties of mid single digits to low double digits on net sales of commercial products that may result from development of SAN711. The potential milestone payments to Saniona consist of up to US $147 million subject to achievement of development and regulatory/commercialization milestones related to potential first and second indications, and up to US $435 million subject to achievement of thresholds of annual net sales of SAN711 worldwide.